NO980155L - Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions - Google Patents

Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions

Info

Publication number
NO980155L
NO980155L NO980155A NO980155A NO980155L NO 980155 L NO980155 L NO 980155L NO 980155 A NO980155 A NO 980155A NO 980155 A NO980155 A NO 980155A NO 980155 L NO980155 L NO 980155L
Authority
NO
Norway
Prior art keywords
zinc
growth hormone
treated
pharmaceutical composition
potassium ions
Prior art date
Application number
NO980155A
Other languages
Norwegian (no)
Other versions
NO980155D0 (en
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmegaard Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO980155L publication Critical patent/NO980155L/en
Publication of NO980155D0 publication Critical patent/NO980155D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Preparat som omfatter et vekst- hormon som er forbehandlet med sink og eventuelt lysin eller kalsiumioner, og som oppviser en svært høy stabilitet mot deamidering, oksidasjon og spalting av peptidbindinger. Stabiliteten til produktet muliggjør lagring og tran- sport derav i en lyofilisert tilstand eller i form av et oppløst eller gjen- oppløst preparat ved omgivelses- temperatur.Preparation comprising a growth hormone pretreated with zinc and possibly lysine or calcium ions, which exhibits very high stability to deamidation, oxidation and cleavage of peptide bonds. The stability of the product enables storage and transport thereof in a lyophilized state or in the form of a dissolved or redissolved preparation at ambient temperature.

NO980155A 1995-07-14 1998-01-13 Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions NO980155D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14
PCT/DK1996/000293 WO1997003692A1 (en) 1995-07-14 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Publications (2)

Publication Number Publication Date
NO980155L true NO980155L (en) 1998-01-13
NO980155D0 NO980155D0 (en) 1998-01-13

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980155A NO980155D0 (en) 1995-07-14 1998-01-13 Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155D0 (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1953173B1 (en) 1999-06-15 2009-11-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ATE424457T1 (en) 2000-01-13 2009-03-15 Genentech Inc HUMAN STRA6 POLYPEPTIDES
KR100890125B1 (en) 2000-02-24 2009-03-24 일라이 릴리 앤드 캄파니 Non-aqueous injectable formulations for extended release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
WO2001072323A2 (en) 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
ATE412009T1 (en) 2000-08-24 2008-11-15 Genentech Inc METHOD FOR INHIBITING IL-22 INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
ATE425463T1 (en) 2003-06-06 2009-03-15 Genentech Inc MODULATION OF THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET
KR100835786B1 (en) 2003-07-08 2008-06-09 제넨테크, 인크. - il-17a/f heterologous polypeptides and therapeutic uses thereof
KR101195291B1 (en) 2003-12-11 2012-10-26 제넨테크, 인크. Methods and compositions for inhibiting C-MET dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
NZ550542A (en) 2004-03-30 2009-03-31 Nsgene As Therapeutic use of a growth factor, NsG33
JP2008518026A (en) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー Adrenocorticotropic hormone analogs and related methods
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
DE602006010072D1 (en) 2005-06-21 2009-12-10 Chen Gang IL-1 BINDING ANTIBODIES AND FRAGMENTS THEREOF
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ATE491026T1 (en) 2005-08-24 2010-12-15 Univ Rockefeller PLY-GBS-LYSINE MUTANTS
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
NZ570300A (en) 2006-02-02 2011-08-26 Trimeris Inc HIV fusion inhibitor peptides with improved biological properties
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CN101437536A (en) 2006-03-23 2009-05-20 诺华有限公司 Anti-tumor cell antigen antibody therapeutics
JP5290148B2 (en) 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Disheveled (Dvl) PDZ modifier
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
BRPI0621841B8 (en) * 2006-07-06 2021-05-25 Daewoong Co Ltd liquid formulation
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
CN101945891A (en) 2007-12-20 2011-01-12 爱克索马技术有限公司 Methods for the treatment of gout
BRPI0917807A2 (en) 2008-08-15 2019-11-19 Forest Laboratories Holdings Ltd stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX2012004303A (en) 2009-10-15 2012-06-25 Genentech Inc Chimeric fibroblast growth factors with altered receptor specificity.
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
JP5878477B2 (en) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Use of vanadium compounds to accelerate bone healing
PL2536742T3 (en) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN106983862A (en) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 For the useful composition of the stable preparation containing protein and method
MX2012012743A (en) 2010-05-03 2012-11-23 Genentech Inc Compositions and methods useful for reducing the viscosity of protein-containing formulations.
KR101924653B1 (en) 2010-06-24 2018-12-03 제넨테크, 인크. Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
JP5921545B2 (en) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド Stable formulation of linaclotide
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
KR101687060B1 (en) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. Moesin modulators and uses thereof
CA2814030C (en) 2010-10-08 2019-04-30 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
SG195261A1 (en) * 2011-06-02 2013-12-30 Baxter Int Formulations of recombinant furin
CN104053449B (en) 2011-08-17 2016-12-07 硬木药品公司 The treatment of gastrointestinal tract disease
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CN104520321A (en) 2012-01-09 2015-04-15 斯克利普斯研究所 Ultralong complementarity determining regions and uses thereof
CN105283196B (en) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 For generate and using conformation-specific antibody method and composition
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
ES2927607T3 (en) 2013-09-13 2022-11-08 Scripps Research Inst Modified therapeutic agents and compositions thereof
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN107921098A (en) 2015-06-17 2018-04-17 加州生物医学研究所 Therapeutic agent of modification and combinations thereof
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
CN110267982B (en) 2016-10-19 2024-02-23 斯克利普斯研究所 Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interaction domains and uses thereof
CN113660953A (en) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 Compositions and methods for stabilizing protein-containing formulations
TW202120551A (en) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 Methods and compositions for promoting and potentiating t‐cell mediated immune responses through adcc targeting of cd39 expressing cells
EP4048405A2 (en) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
JP2024518433A (en) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス Prevention and treatment of chemotherapy-induced neuropathic pain
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
CA2226523A1 (en) 1997-02-06
NO980155D0 (en) 1998-01-13
HUP9802287A2 (en) 1999-02-01
HUP9802287A3 (en) 2000-10-30
EP0839049A1 (en) 1998-05-06
CZ9498A3 (en) 1998-06-17
CN1190897A (en) 1998-08-19
IL122583A0 (en) 1998-06-15
WO1997003692A1 (en) 1997-02-06
PL324379A1 (en) 1998-05-25
JPH11509212A (en) 1999-08-17
KR19990028981A (en) 1999-04-15
ZA965368B (en) 1997-01-14
AU715997B2 (en) 2000-02-17
BR9609741A (en) 1999-03-16
AU6353496A (en) 1997-02-18
MX9800358A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
NO980155L (en) Stabilized pharmaceutical composition comprising a growth hormone pre-treated with zinc and optionally lysine or potassium ions
HU9401831D0 (en) Stabilized pharmaceutical formulations comprising growth hormone and asparagine
AU610636B2 (en) Stabilised human protein preparations
MX9207374A (en) PHARMACEUTICAL PREPARATION COMPRISING A GROWTH HORMONE OR A DERIVATIVE OF THE GROWTH HORMONE AND HISTIDINE OR A DERIVATIVE OF HISTIDINE.
ATE175446T1 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND THEIR USES IN CONNECTION WITH CD4 RECEPTOR BINDING
ATE156361T1 (en) PROTEIN-CONTAINED MEDICINAL PRODUCTS WITH DELAYED RELEASE
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
DE69434588D1 (en) Delayed release of insulinotropin (GLP-1)
AU4280600A (en) Supplement for restoring growth hormone levels
IL115590A (en) Pharmaceutical formulation comprising a growth hormone and isoleucine
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
ES2187782T3 (en) PROCEDURE FOR THE PRODUCTION OF POLYPEPTIDES.
PT785795E (en) PHARMACEUTICAL COMPOSITION
AR034226A2 (en) PERFECTED PROCEDURE TO STABILIZE PROTEINS.
GB9801420D0 (en) Frozen food product
DK1014948T3 (en) Lyophilized pharmaceutical composition intended to mimic a drug based on proteins or polypeptides
PE20030608A1 (en) COMPOSITION AND METHOD TO TREAT DIABETES
WO1999037782A3 (en) Frozen food product
DE58906338D1 (en) Combination of angiotensin converting enzyme inhibitors with potassium channel modulators and their use in drugs.
SE9003844D0 (en) NAERINGSTILLSATS
NO980103L (en) Stabilized pharmaceutical composition comprising a growth hormone and a peptide comprising at least one basic amino acid residue and at least one acidic amino acid residue
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
AU1503697A (en) Method for cleaving chimeric protein using processing enzyme
EP1161945A3 (en) Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds
AU2003264535A1 (en) Tumor antigen protein and utilization thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application